Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension

Figures

• 

  Fig. 1. Study design. *Patients taking previous antihypertensive agents were required to participate in a 3-week washout (days − 21 to − 1). †If the patient’s previous antihypertensive treatment included amlodipine or chlorthalidone, then the washout was extended to 4 weeks (days − 28 to − 1). ‡Patients who had not received antihypertensive treatment within 28 days prior to screening entered the run-in period as soon as all inclusion and exclusion criteria, including laboratory results, were verified. AZL-M, azilsartan medoxomil; ET, early termination; N/A, not applicable; QD, once daily

• 

  Fig. 2. Patient disposition. Patients could have had more than one reason for discontinuation; only the primary reason is presented. AE, adverse event; AZL-M, azilsartan medoxomil

• 

  Fig. 3. Least squares mean change from baseline to week 6 in trough sitting clinic systolic blood pressure and sitting clinic diastolic blood pressure. aThe LS mean difference in change from baseline (95% CI) in AZL-M 40 mg versus placebo (mm Hg [95% CI]). bThe LS mean difference in change from baseline (95% CI) in AZL-M 80 mg versus placebo (mm Hg [95% CI]). ***p < 0.001 compared with placebo. Overall treatment effect is statistically significant at 0.05 at all visits for both trough scSBP and scDBP. AZL-M, azilsartan medoxomil; CI, confidence interval; LS, least squares; scDBP, sitting clinic diastolic blood pressure; scSBP, sitting clinic systolic blood pressure

• 

  Fig. 4. Proportion of patients who achieved sitting clinic systolic blood pressure and/or sitting clinic diastolic blood pressure response at week 6. AZL-M, azilsartan medoxomil; CI, confidence interval; scDBP, sitting clinic diastolic blood pressure; scSBP, sitting clinic systolic blood pressure; SE, standard error

• 

  Fig. 5. Least squares mean change from baseline to week 6 in trough sitting clinic systolic blood pressure and sitting clinic diastolic blood pressure by (a) age, (b) sex, and (c) diabetes status. *p < 0.05 compared with placebo; **p < 0.01 compared with placebo; ***p < 0.001 compared with placebo. AZL-M, azilsartan medoxomil; LS, least squares; scDBP, sitting clinic diastolic blood pressure; scSBP, sitting clinic systolic blood pressure